3 Jan 2022 , 02:18 PM
Natco Pharma‘s wholly-owned subsidiary, NATCO Pharma Inc. USA, has completed the acquisition of Dash Pharmaceuticals LLC (“Dash”), a New Jersey-based entity.
Pursuant to this, Dash will become a 100% wholly-owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
The acquisition was valued at $18 million.
Natco Pharma said that this acquisition provides NATCO with a platform to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.
Dash is a front-end pharmaceutical sales, marketing and distribution entity in the USA which is expected to have Net Sales of approximately $15 million for the financial year ending December 2021.
At around 2.16 pm, Natco Pharma was trading at Rs914 per piece up by 1.1% on Sensex. The stock was near the day’s high of Rs919.95 per piece.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
